Melanoma Imaging with Highly Specific PET Probes: Ready for Prime Time?

Minn, Heikki; Vihinen, Pia

doi:10.2967/jnumed.110.080523

Cited by 7 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, several scintigraphic studies have been developed over the past years, based on tracers related to specific characteristics of melanoma cells. 20 Since α-MSH (α-melanocyte-stimulating hormone) receptor MC1R (melanocortin type 1 receptor) is overexpressed in most murine and human melanomas, it has been investigated as a target for selective imaging and therapeutic agents. 21−23 [ 18 F]Labeled small synthetic peptide [ 18 F]FB-NAPamide demonstrated that it could differentiate B16/F10 and A375M with high and low MC1R expression, respectively, but this tracer showed only moderate tumor uptake and retention.…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma

et al. 2013

View full text Add to dashboard Cite

Our project deals with a multimodal approach using a single fluorinated and iodinated melanin-targeting structure and offering both imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therapy/iodine-131) of melanoma. Six 6-iodoquinoxaline-2-carboxamide derivatives with various side chains bearing fluorine were synthesized and radiofluorinated, and their in vivo biodistribution was studied by PET imaging in B16Bl6 primary melanoma-bearing mice. Among this series, [(18)F]8 emerged as the most promising compound. [(18)F]8 was obtained by a fully automated radiosynthesis process within 57 min with an overall radiochemical yield of 21%, decay-corrected. PET imaging of [(18)F]8 demonstrated very encouraging results as early as 1 h postinjection with high tumor uptake (14.33% ± 2.11% ID/g), high contrast (11.04 ± 2.87 tumor-to-muscle ratio), and favorable clearance properties. These results, associated with the previously reported pharmacokinetic properties and dosimetry of 8, make it a potential agent for both PET imaging and targeted radionuclide therapy of melanoma.

show abstract

Section: ■ Introductionmentioning

confidence: 99%

“…Moreover, the use of this nonspecific radiotracer may be limited by the risk of false-positives due to abnormal inflammatory area uptake, for example. Thus, several scintigraphic studies have been developed over the past years, based on tracers related to specific characteristics of melanoma cells …”

Section: Introductionmentioning

confidence: 99%

Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Fusion of PET and CT images facilitates morphologic detection of lesions picked up by PET, thus giving rise to markedly enhanced diagnostic validity [104]. At present, numerous other melanoma-sensitive tracers are under -mostly preclinicalevaluation and will herein not be dealt with [131]. PET and PET/CT have undergone rapid technological developments.…”

Section: S Reskementioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

181

148

View full text Add to dashboard Cite

“…Such an approach requires a highly sensitive and quantifiable tumor-specific marker, e.g., by using PET tracers. The developments in melanoma-specific markers is recently reviewed in [97]. In this respect, novel compounds that target melanin biosynthesis and metallopeptides binding to melanocortin type 1 receptor, which are overexpressed in melanoma, are promising agents [41, 42, 57].…”

Section: Immunological Targets For Imaging In Humansmentioning

confidence: 99%

In vivo imaging of therapy-induced anti-cancer immune responses in humans

Aarntzen

Srinivas

Radu³

et al. 2012

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Immunotherapy aims to re-engage and revitalize the immune system in the fight against cancer. Research over the past decades has shown that the relationship between the immune system and human cancer is complex, highly dynamic, and variable between individuals. Considering the complexity, enormous effort and costs involved in optimizing immunotherapeutic approaches, clinically applicable tools to monitor therapy-induced immune responses in vivo are most warranted. However, the development of such tools is complicated by the fact that a developing immune response encompasses several body compartments, e.g., peripheral tissues, lymph nodes, lymphatic and vascular systems, as well as the tumor site itself. Moreover, the cells that comprise the immune system are not static but constantly circulate through the vascular and lymphatic system. Molecular imaging is considered the favorite candidate to fulfill this task. The progress in imaging technologies and modalities has provided a versatile toolbox to address these issues. This review focuses on the detection of therapy-induced anticancer immune responses in vivo and provides a comprehensive overview of clinically available imaging techniques as well as perspectives on future developments. In the discussion, we will focus on issues that specifically relate to imaging of the immune system and we will discuss the strengths and limitations of the current clinical imaging techniques. The last section provides future directions that we envision to be crucial for further development.

show abstract

Melanoma Imaging with Highly Specific PET Probes: Ready for Prime Time?

Cited by 7 publications

References 17 publications

Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma

Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

In vivo imaging of therapy-induced anti-cancer immune responses in humans

Contact Info

Product

Resources

About